AIM ImmunoTech begins trading under new ticker AIMI

OCALA, Fla. - AIM ImmunoTech Inc. (OTC Pink: AIMI), a company specializing in the development of therapeutics for cancers, immune disorders, and viral diseases including COVID-19, announced today that its common stock has commenced trading on the Pink Open Market with the ticker symbol AIMI. With a market capitalization of approximately $92 million, the stock has seen significant volatility, declining over 20% year-to-date according to InvestingPro data. The company also confirmed that its Special Meeting to discuss a potential reverse stock split is scheduled for April 30, 2025.

AIM ImmunoTech's primary focus is on Ampligen® (rintatolimod), a first-in-class investigational drug. Ampligen® is a double-stranded RNA (dsRNA) and a highly selective TLR3 agonist immunomodulator, which is currently under clinical trials. The drug is being tested for a variety of significant global health issues, encompassing various cancers, viral diseases, and immune system disorders. InvestingPro analysis shows the company maintains a strong balance sheet with more cash than debt, though it's currently burning through cash at a concerning rate.

The announcement follows the filing of AIM's Definitive Proxy Statement on April 2, 2025, which provides additional details regarding the company's operations and upcoming Special Meeting. Shareholders and interested parties are encouraged to review this document for further information. According to InvestingPro, which offers comprehensive analysis through its Pro Research Reports covering over 1,400 stocks, the company's revenue stands at $40.4 million for the last twelve months, with a gross profit margin of 31.3%.

AIM ImmunoTech has made clear that while the data and clinical successes to date are promising, they do not guarantee that Ampligen will receive approval as a prophylactic or therapeutic treatment for any specific indication. The company highlights that there are numerous risks and uncertainties associated with drug development, and it cautions investors to consider the risk factors identified in its most recent Form 10-K, as well as those in subsequent Form 10-Q or Form 8-K filings with the U.S. Securities and Exchange Commission.

The company's forward-looking statements are protected under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, but it has stated that it does not commit to updating any forward-looking statements post-publication to reflect events or circumstances arising after the date of the press release.

This news article is based on a press release statement from AIM ImmunoTech Inc.

In other recent news, Aimia reported a strong finish to 2024 with a 27% increase in revenue, totaling $127.2 million, and a significant reduction in net loss by $17.8 million to $42.1 million. Despite these positive developments, the company slightly missed earnings per share (EPS) expectations, with an actual EPS of -$0.10 compared to the forecast of -$0.09. Aimia's performance was bolstered by its holdings, Bizetto and Cortland, which contributed to the revenue surge. Analysts from Citi Cowen noted the company's strategic focus on reducing costs and enhancing shareholder value, with plans to improve adjusted EBITDA in 2025.

Meanwhile, AIM ImmunoTech is facing delisting from the NYSE American exchange due to persistently low stock prices. The company plans to appeal the decision but has acknowledged the uncertainty of a successful outcome. AIM ImmunoTech's common stock is expected to begin trading on the Pink Open Market soon. The company's investigational drug, Ampligen®, is undergoing clinical trials for various serious diseases. AIM ImmunoTech has filed a Current Report on Form 8-K with the SEC to provide further details on the situation.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.